A Comparison of Traditional Versus Response-based Involved-Field Radiation Therapy on Clinical Target Volume and Organs-at-Risk for Pediatric Rapid Early Responders With High-Risk Hodgkin Lymphoma

2012 ◽  
Vol 84 (3) ◽  
pp. S642
Author(s):  
J.E. Wilson ◽  
M. South ◽  
B. Teh ◽  
B. Butler ◽  
A. Paulino
Keyword(s):  
At Risk ◽  
Radiation Therapy ◽  
High Risk ◽  
Hodgkin Lymphoma ◽  
Clinical Target Volume ◽  
Organs At Risk ◽  
Target Volume ◽  
Field Radiation ◽  
Involved Field

Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy

2014 ◽  
Vol 112 (2) ◽  
pp. 279-283 ◽  
Author(s):  
David J. Mulvihill ◽  
Kevin McMichael ◽  
Sharad Goyal ◽  
Richard Drachtman ◽  
Aaron Weiss ◽  
...  
Keyword(s):  
At Risk ◽  
Radiation Therapy ◽  
Organs At Risk ◽  
Field Radiation ◽  
Involved Field

scholarly journals Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3744
Author(s):  
Pierre Loap ◽  
Ludovic De Marzi ◽  
Alfredo Mirandola ◽  
Remi Dendale ◽  
Alberto Iannalfi ◽  
...  
Keyword(s):  
At Risk ◽  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Proton Therapy ◽  
Early Stage ◽  
Organs At Risk ◽  
Intensity Modulated Radiation Therapy ◽  
Progression Free Survival ◽  
Treatment Techniques ◽  
Increased Risk

Consolidative radiation therapy for early-stage Hodgkin lymphoma (HL) improves progression-free survival. Unfortunately, first-generation techniques, relying on large irradiation fields, were associated with an increased risk of secondary cancers, and of cardiac and lung toxicity. Fortunately, the use of smaller target volumes combined with technological advances in treatment techniques currently allows efficient organs-at-risk sparing without altering tumoral control. Recently, proton therapy has been evaluated for mediastinal HL treatment due to its potential to significantly reduce the dose to organs-at-risk, such as cardiac substructures. This is expected to limit late radiation-induced toxicity and possibly, second-neoplasm risk, compared with last-generation intensity-modulated radiation therapy. However, the democratization of this new technique faces multiple issues. Determination of which patient may benefit the most from proton therapy is subject to intense debate. The development of new effective systemic chemotherapy and organizational, societal, and political considerations might represent impediments to the larger-scale implementation of HL proton therapy. Based on the current literature, this critical review aims to discuss current challenges and controversies that may impede the larger-scale implementation of mediastinal HL proton therapy.

scholarly journals Interobserver variation in clinical target volume and organs at risk segmentation in post-parotidectomy radiotherapy: can segmentation protocols help?

2012 ◽  
Vol 85 (1016) ◽  
pp. e530-e536 ◽  
Author(s):  
M Mukesh ◽  
R Benson ◽  
R Jena ◽  
A Hoole ◽  
T Roques ◽  
...  
Keyword(s):  
At Risk ◽  
Clinical Target Volume ◽  
Organs At Risk ◽  
Target Volume ◽  
Interobserver Variation
Sign in / Sign up

Export Citation Format

Share Document